Jade Biosciences (JBIO) Cantor Global Healthcare Conference 2025 summary

Company background and strategy

• Founded by former Chinook Therapeutics leaders, leveraging expertise from both large pharma and biotech to drive efficient drug development and commercialization.

• Focused on best-in-class therapeutics for autoimmune diseases, with three assets sourced from Paragon Therapeutics.

• Lead asset, JADE101, targets anti-APRIL for IgA nephropathy (IgAN), aiming for disease modification and kidney function stabilization.

• Closed a reverse merger in April, raising $300 million to fund operations through 2027.

• Emphasizes a lean, data-driven approach, leveraging learnings from prior industry experience to accelerate development.

Pipeline and clinical development

• JADE101 is a high-affinity, half-life extended anti-APRIL antibody, designed for subcutaneous dosing every eight weeks or less.

• Phase I healthy volunteer study initiated, with interim data expected in the first half of 2026; study includes four cohorts and focuses on PK/PD and biomarker analysis.

• Preclinical data show JADE101 outperforms first-generation anti-APRILs in half-life and IgA reduction, supporting best-in-class potential.

• Two additional assets: 201 (B-cell depleting, entering clinic in 1H 2025) and 301 (targeting clinic in 1H 2027), both leveraging Paragon's protein engineering.

• Plans to use biomarker-rich data to expedite clinical development, potentially moving quickly into patient trials and phase III.

Market opportunity and competitive landscape

• IgAN market estimated at $10 billion+, with approximately 170,000 patients in the U.S. alone.

• KDIGO guidelines and evolving risk definitions are expected to expand the eligible patient pool.

• Competitors include Sibeprenlimab (Otsuka) and zigakibart (Novartis), but JADE101 aims for superior efficacy and dosing convenience.

• Regulatory strategy informed by prior agents, with expectations for initial approval in high-risk patients and broader label upon full approval.

• Future trials will include patients on contemporary therapies to demonstrate additive benefit.